Loading...

We've got a brand new version of Simply Wall St! Try it out

StillCanna

CNSX:STIL
Snowflake Description

Mediocre balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
STIL
CNSX
CA$50M
Market Cap
  1. Home
  2. CA
  3. Pharmaceuticals & Biotech
Company description

StillCanna Inc., a life sciences company, focuses on cannabidiol extraction in Europe. The last earnings update was 82 days ago. More info.


Add to Portfolio Compare Print
  • StillCanna has significant price volatility in the past 3 months.
STIL Share Price and Events
7 Day Returns
-17.9%
CNSX:STIL
-5.9%
CA Pharmaceuticals
1.3%
CA Market
1 Year Returns
-6.1%
CNSX:STIL
-46.7%
CA Pharmaceuticals
-0.1%
CA Market
STIL Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
StillCanna (STIL) -17.9% -37.8% -53.5% -6.1% 820% 820%
CA Pharmaceuticals -5.9% -3.4% -24.8% -46.7% 217.3% 286.4%
CA Market 1.3% 4.2% 1.6% -0.1% 8.4% 5.7%
1 Year Return vs Industry and Market
  • STIL outperformed the Pharmaceuticals industry which returned -46.7% over the past year.
  • STIL underperformed the Market in Canada which returned -0.1% over the past year.
Price Volatility
STIL
Industry
5yr Volatility vs Market

Value

 Is StillCanna undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for StillCanna. This is due to cash flow or dividend data being unavailable. The share price is CA$0.46.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for StillCanna's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are StillCanna's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
CNSX:STIL PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-04-30) in CAD CA$-0.38
CNSX:STIL Share Price ** CNSX (2019-09-20) in CAD CA$0.46
Canada Pharmaceuticals Industry PE Ratio Median Figure of 13 Publicly-Listed Pharmaceuticals Companies 15.3x
Canada Market PE Ratio Median Figure of 539 Publicly-Listed Companies 14.14x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of StillCanna.

CNSX:STIL PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= CNSX:STIL Share Price ÷ EPS (both in CAD)

= 0.46 ÷ -0.38

-1.2x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • StillCanna is loss making, we can't compare its value to the CA Pharmaceuticals industry average.
  • StillCanna is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does StillCanna's expected growth come at a high price?
Raw Data
CNSX:STIL PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.2x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Canada Pharmaceuticals Industry PEG Ratio Median Figure of 7 Publicly-Listed Pharmaceuticals Companies 1.56x
Canada Market PEG Ratio Median Figure of 245 Publicly-Listed Companies 1.02x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for StillCanna, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on StillCanna's assets?
Raw Data
CNSX:STIL PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-04-30) in CAD CA$0.06
CNSX:STIL Share Price * CNSX (2019-09-20) in CAD CA$0.46
Canada Pharmaceuticals Industry PB Ratio Median Figure of 151 Publicly-Listed Pharmaceuticals Companies 2.36x
Canada Market PB Ratio Median Figure of 2,457 Publicly-Listed Companies 1.43x
CNSX:STIL PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= CNSX:STIL Share Price ÷ Book Value per Share (both in CAD)

= 0.46 ÷ 0.06

8.01x

* Primary Listing of StillCanna.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • StillCanna is overvalued based on assets compared to the CA Pharmaceuticals industry average.
X
Value checks
We assess StillCanna's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. StillCanna has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is StillCanna expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as StillCanna has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
97.7%
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is StillCanna expected to grow at an attractive rate?
  • Unable to compare StillCanna's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare StillCanna's earnings growth to the Canada market average as no estimate data is available.
  • Unable to compare StillCanna's revenue growth to the Canada market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
CNSX:STIL Future Growth Rates Data Sources
Data Point Source Value (per year)
Canada Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 97.7%
Canada Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 56.5%
Canada Market Earnings Growth Rate Market Cap Weighted Average 12.6%
Canada Market Revenue Growth Rate Market Cap Weighted Average 5.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
CNSX:STIL Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
CNSX:STIL Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2019-04-30 -2 -14
2019-01-31 -1 -1
2018-10-31 -1 -1
2018-07-31 0 -1
2018-04-30 0 0
2018-01-31 0 0
2017-10-31 0 0
2017-07-31 0 0
2017-04-30 0 0
2017-01-31 0 0
2016-10-31 0 0
2016-07-31 0 0

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if StillCanna is high growth as no earnings estimate data is available.
  • Unable to determine if StillCanna is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
CNSX:STIL Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from StillCanna Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:STIL Past Financials Data
Date (Data in CAD Millions) EPS *
2019-04-30 -0.38
2019-01-31 -0.04
2018-10-31 -0.05
2018-07-31 -0.03
2018-04-30 -0.02
2018-01-31 -0.02
2017-10-31 -0.02
2017-07-31 -0.03
2017-04-30 0.00
2017-01-31 0.00
2016-10-31 -0.01
2016-07-31 -0.01

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if StillCanna will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of STIL’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. StillCanna's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. StillCanna's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess StillCanna's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
StillCanna has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has StillCanna performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare StillCanna's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • StillCanna does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare StillCanna's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare StillCanna's 1-year growth to the CA Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
StillCanna's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from StillCanna Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:STIL Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-04-30 -13.51 1.91
2019-01-31 -1.16 0.86
2018-10-31 -1.03 0.71
2018-07-31 -0.60 0.28
2018-04-30 -0.37 0.04
2018-01-31 -0.31 0.01
2017-10-31 -0.29 0.01
2017-07-31 -0.29 0.01
2017-04-30 -0.03 0.02
2017-01-31 -0.04 0.03
2016-10-31 -0.05 0.04
2016-07-31 -0.07 0.05
2016-04-30 -0.15 0.06
2016-01-31 -0.16 0.07
2015-10-31 -0.35 0.26
2015-07-31 -0.36 0.28
2015-04-30 -0.32 0.29
2015-01-31 -0.32 0.28
2014-10-31 -0.12 0.09
2014-07-31 -0.09 0.06
2014-04-30 -0.05 0.04
2014-01-31 -0.05 0.04
2013-10-31 -0.05 0.04
2013-07-31 -0.06 0.05
2013-04-30 -0.06 0.05
2013-01-31 -0.09 0.07
2012-10-31 -0.08 0.07

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if StillCanna has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if StillCanna has efficiently used its assets last year compared to the CA Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if StillCanna improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess StillCanna's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
StillCanna has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is StillCanna's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up StillCanna's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • StillCanna is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • StillCanna's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of StillCanna's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 10.2x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from StillCanna Company Filings, last reported 4 months ago.

CNSX:STIL Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-04-30 3.42 0.07 0.08
2019-01-31 3.65 0.00 2.31
2018-10-31 3.78 0.00 3.13
2018-07-31 0.07 0.00 0.10
2018-04-30 0.38 0.08 0.16
2018-01-31 0.41 0.06 0.25
2017-10-31 0.20 0.04 0.02
2017-07-31 0.20 0.02 0.00
2017-04-30 0.22 0.01 0.00
2017-01-31 0.22 0.01 0.00
2016-10-31 0.23 0.01 0.00
2016-07-31 0.23 0.00
2016-04-30 0.07 0.00 0.00
2016-01-31 0.08 0.00 0.01
2015-10-31 0.09 0.00 0.10
2015-07-31 0.12 0.00 0.12
2015-04-30 0.21 0.00 0.16
2015-01-31 0.24 0.00 0.18
2014-10-31 0.44 0.00 0.31
2014-07-31 0.45 0.00 0.43
2014-04-30 0.50 0.00 0.46
2014-01-31 0.53 0.00 0.52
2013-10-31 0.53 0.00 0.53
2013-07-31 0.54 0.00 0.55
2013-04-30 0.55 0.00 0.55
2013-01-31 0.57 0.00 0.57
2012-10-31 0.58 0.00 0.58
  • StillCanna's level of debt (2%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if StillCanna's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • StillCanna has less than a year of cash runway based on current free cash flow.
  • StillCanna has less than a year of cash runway if free cash flow continues to grow at historical rates of 138.9% each year.
X
Financial health checks
We assess StillCanna's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. StillCanna has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is StillCanna's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from StillCanna dividends.
If you bought CA$2,000 of StillCanna shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate StillCanna's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate StillCanna's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
CNSX:STIL Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
North America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 2.8%
Canada Market Average Dividend Yield Market Cap Weighted Average of 334 Stocks 3.5%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.1%
Canada Bottom 25% Dividend Yield 25th Percentile 2%
Canada Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as StillCanna has not reported any payouts.
  • Unable to verify if StillCanna's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of StillCanna's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as StillCanna has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess StillCanna's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can StillCanna afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. StillCanna has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of StillCanna's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Jason Dussault
COMPENSATION CA$14,000
TENURE AS CEO 1.4 years
CEO Bio

Mr. Jason Dussault has been the Chief Executive Officer of StillCanna Inc. since April 20, 2018 and Director since May 22, 2018 and serves as its President. Mr. Dussault was the Founder and served as the Chief Executive Officer of Pure Energy Minerals Limited from October 18, 2012 to May 10, 2013. Mr. Dussault was a Member of Advisory Board at Zadar Ventures Ltd. since April 25, 2016 until January 2018. He served as a Director of Pure Energy Minerals Limited from October 18, 2012 to December 30, 2013.

CEO Compensation
  • Insufficient data for Jason to compare compensation growth.
  • Jason's remuneration is lower than average for companies of similar size in Canada.
Management Team Tenure

Average tenure and age of the StillCanna management team in years:

1.4
Average Tenure
47
Average Age
  • The average tenure for the StillCanna management team is less than 2 years, this suggests a new team.
Management Team

Jason Dussault

TITLE
CEO, President & Director
COMPENSATION
CA$14K
TENURE
1.4 yrs

Joel Leonard

TITLE
Chief Financial Officer
COMPENSATION
CA$15K
AGE
33
TENURE
1.3 yrs

Richard Haslinger

TITLE
Consultant
AGE
55
TENURE
4 yrs

Jason Leikam

TITLE
Consultant
AGE
48
TENURE
4 yrs

Adam Kim

TITLE
Promoter
AGE
46

Marc Crimeni

TITLE

Shae De Jaray

TITLE
COO, Senior Engineer & Director
TENURE
0.6 yrs
Board of Directors Tenure

Average tenure of the StillCanna board of directors in years:

0.7
Average Tenure
  • The average tenure for the StillCanna board of directors is less than 3 years, this suggests a new board.
Board of Directors

Shae De Jaray

TITLE
COO, Senior Engineer & Director
TENURE
0.2 yrs

C.K. Cheung

TITLE
Member of Advisory Board
TENURE
3.3 yrs

Jason Dussault

TITLE
CEO, President & Director
COMPENSATION
CA$14K
TENURE
1.3 yrs

Warren Robinson

TITLE
Director
TENURE
0.3 yrs

Bill MacDonald

TITLE
Independent Director
AGE
51
TENURE
0.3 yrs

Krystyna Skalicka-Wozniak

TITLE
Member of Advisory Board
TENURE
0.7 yrs

Krzysztof Wojtanowski

TITLE
Member of Advisory Board
TENURE
0.7 yrs

Lidia Grabowska

TITLE
Member of Advisory Board
TENURE
0.7 yrs

Thomas Svensson

TITLE
Member of Advisory Board
TENURE
0.7 yrs

Bogdan Wenta

TITLE
Member of Advisory Board
TENURE
0.7 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by StillCanna individual insiders in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
28. Aug 19 Buy Jason Dussault Individual 09. Feb 19 28. Aug 19 80,000 CA$0.76 CA$50,796
X
Management checks
We assess StillCanna's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. StillCanna has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Announcing: StillCanna (CNSX:STIL) Stock Soared An Exciting 800% In The Last Three Years

See our latest analysis for StillCanna StillCanna hasn't yet reported any revenue, so it's as much a business idea as an actual business. … Investors will be hoping that StillCanna can make progress and gain better traction for the business, before it runs low on cash. … CNSX:STIL Historical Debt, July 25th 2019 In reality it's hard to have much certainty when valuing a business that has neither revenue or profit.

Simply Wall St -

Company Info

Description

StillCanna Inc., a life sciences company, focuses on cannabidiol extraction in Europe. The company was formerly known as EVI Global Group Developments Corp. and changed its name to StillCanna Inc. in March 2019. The company is headquartered in Vancouver, Canada.

Details
Name: StillCanna Inc.
STIL
Exchange: CNSX
Founded:
CA$49,599,220
107,824,392
Website: http://www.stillcanna.com
Address: StillCanna Inc.
504 - 905 West Pender Street,
Vancouver,
British Columbia, V6C 1L6,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
CNSX STIL Common Shares Canadian National Stock Exchange CA CAD 01. May 2012
OTCPK SCNN.F Common Shares Pink Sheets LLC US USD 01. May 2012
DB 484 Common Shares Deutsche Boerse AG DE EUR 01. May 2012
Number of employees
Current staff
Staff numbers
0
StillCanna employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/09/22 00:27
End of day share price update: 2019/09/20 00:00
Last earnings filing: 2019/07/02
Last earnings reported: 2019/04/30
Last annual earnings reported: 2018/07/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.